🇺🇸 FDA
Pipeline program

TARA-002

TARA-002-301

Phase 3 small_molecule active

Quick answer

TARA-002 for Bladder (Urothelial, Transitional Cell) Cancer is a Phase 3 program (small_molecule) at Protara Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Protara Therapeutics
Indication
Bladder (Urothelial, Transitional Cell) Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials